DSIP / Emideltide
$Sleep-wake / withdrawal research peptide; Old human studies, unresolved mechanism
DSIP stands for delta sleep-inducing peptide. The FDA name used in the 2026 compounding review is Emideltide. It is a nine-amino-acid peptide that became famous because early rabbit experiments suggested it could increase slow-wave, delta-like EEG activity. In modern terms, it should be read as a sleep-wake and neuroendocrine research peptide, not as a proven sleeping pill.
DSIP has more human history than many gray-market peptides, but that history is old, small, and mixed. A few studies explored insomnia, narcolepsy, alcohol withdrawal, and opioid withdrawal.
Later reviews emphasize that the natural DSIP system remains poorly characterized: no clearly validated DSIP gene, precursor, receptor, or single mechanism explains all reported effects. Separate the name from the proof. “Sleep-inducing” is a historical label, not a guarantee.
Focus on three uncertainties: whether the measured DSIP-like material is truly the same peptide, whether exogenous DSIP reaches the relevant brain targets by a given route, and whether the effect is circadian modulation rather than direct sedation.
Classification details
- DSIP is a synthetic version of a nonapeptide originally isolated from rabbit cerebral venous blood after hypnogenic electrical stimulation.
- The commonly cited sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, abbreviated WAGGDASGE.
- The molecular formula is C35H48N10O15 and the molecular weight is about 848.8 Da.
- The FDA refers to DSIP as Emideltide in the 2026 Pharmacy Compounding Advisory Committee materials.
- The substances being discussed are Emideltide free base and Emideltide acetate.
- In this guide, DSIP, delta sleep-inducing peptide, and Emideltide refer to the same standard nonapeptide unless a modified analog is explicitly named.
- Classification is difficult. It is commonly grouped as a neuropeptide or sleep-wake regulatory peptide.
- It is not a benzodiazepine, non-benzodiazepine hypnotic, orexin antagonist, melatonin agonist, opioid, or approved detoxification medication.
- It belongs in the “old clinical research / unresolved mechanism” category rather than in the “proven prescription sleep drug” category.
- DSIP/emideltide is a sleep-related neuropeptide research compound with unresolved biology, not a reliable sedative. This entry uses the name emideltide, because FDA materials use that term.
- No single DSIP receptor has been validated which is the central scientific limitation.
- Early work treated DSIP as a candidate endogenous sleep factor because of delta-wave EEG findings in animals. Later reviews concluded that the sleep-factor hypothesis is weakly documented and that DSIP-like immunoreactivity may reflect related peptides or fragments rather than one clean endocrine system.
- The most defensible mechanism language is broad: DSIP appears to interact with sleep-wake regulation, stress-axis signaling, neuroendocrine tone, and possibly opioid-related pathways.
- Proposed effects include modulation of ACTH/corticosterone stress responses, interactions with hypothalamic systems, changes in endogenous opioid signaling, and altered neuronal excitability.
- These are mechanistic hypotheses, not confirmed clinical mechanisms.
- DSIP is not a simple sedative. In some narcolepsy research it was reported to reduce daytime sleep attacks and improve alertness, which is the opposite of what a pure hypnotic model would predict.
- A more careful interpretation is that DSIP may influence sleep-wake organization or circadian regulation, but the direction and clinical reliability depend heavily on subject, route, timing, and study design.
- Proposed mechanisms touch sleep regulation, stress axis, pain, and neuroendocrine signaling, but the mechanism is not settled. It does not directly induce delta sleep in a predictable, drug-like way.